Paradigm Diagnostics develops the Paradigm Cancer Diagnostic (PCDx), which uses proprietary sequencing, bioinformatics and technology to identify evidence-based treatment options that may improve a cancer patient’s progression-free survival. The company delivers comprehensive next-generation sequencing results, including mutational load, from a single slide and returns results in 3–5 business days. Led by co-founder, chairman and CEO David Mallery, Paradigm emphasizes rapid, clinically actionable genomic reporting. The recently announced financing will support rapid commercialization of the PCDx test. The article does not disclose revenue or user metrics. The company is based in Phoenix, AZ. Paradigm Diagnostics is a Phoenix, AZ-based developer of cancer diagnostic tests. It has developed PCDx, a clinical-grade NGS-based test designed to identify genomic and proteomic alterations in tumor DNA, RNA and protein to inform personalized cancer treatment. PCDx interrogates the most relevant genomic targets at over 5,000x average depth of coverage and reports 72 therapeutic associations, with results typically delivered in 4-5 business days. The company intends to use the funds from the Series B first close to build out its commercial team and establish research collaborations. The company is led by David Mallery, President and CEO.

Total raised

$22M

Funding rounds

2

Latest round

Series B

Latest activity

May 2019